Loncar Cancer Immunotherapy ETF (CNCR)
|Ex-Dividend Date||Dec 29, 2021|
|Day's Range||14.62 - 14.89|
|Inception Date||Oct 13, 2015|
The Loncar Cancer Immunotherapy ETF (CNCR) is an exchange-traded fund that is based on the Loncar Cancer Immunotherapy index. The fund tracks an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs. CNCR was launched on Oct 13, 2015 and is managed by Loncar.
Top 10 Holdings41.26% of assets
|Janux Therapeutics, Inc.||JANX||5.65%|
|RAPT Therapeutics, Inc.||RAPT||5.10%|
|Iovance Biotherapeutics, Inc.||IOVA||4.17%|
|IGM Biosciences, Inc.||IGMS||3.96%|
|Allogene Therapeutics, Inc.||ALLO||3.65%|
|CRISPR Therapeutics AG||CRSP||3.62%|
|Dec 29, 2021||$1.85334||Dec 31, 2021|
|Dec 30, 2020||$0.28812||Jan 4, 2021|
|Dec 28, 2017||$0.3502||Jan 2, 2018|
|Dec 29, 2015||$0.10551||Jan 4, 2016|
Concerns over higher inflation and rising rates continued to weigh on investors' sentiments. This has provided a compelling opportunity for investors to buy cheap heading into 2023.
The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.
Reflecting what it considers the vast potential of life sciences companies, Bain Capital is making another huge bet on the industry. The Boston-based investment firm has raised $1.9 billion in a new f...
Both stock index ETFs and biotech stocks and ETFs have been on a tear lately thanks to promising coronavirus vaccine developments from several major pharmaceutical companies. But this week, the U.K. b...
Healthcare stocks and ETFs are continuing to outperform as investors are optimistic about an upcoming vaccine for the coronavirus, which has been a blight on the globe since early this year. There has...
We have highlighted ETFs that were at the forefront of the market rebound on Sep 9 and will continue to do so if market sentiments remain positive.
Specialized health-care exchange-traded funds outperformed the broader stock market Wednesday even as stocks rebounded from a sell-off that left the Nasdaq Composite Index in correction territory. Th...
Per the latest data from an early stage clinical trial, Moderna's experimental coronavirus vaccine is successfully producing neutralizing antibodies and T-cells in older adults.
Stock indexes and ETFs rocketed higher and are continuing the uptrend in trading Wednesday after Moderna said its coronavirus vaccine generated antibodies in elderly patients for the first time, creat...
Stock futures rocketed higher and are continuing the uptrend in overnight trading on Tuesday after Moderna said its coronavirus vaccine generated antibodies in all patients in an early trial, creating...
With the race to find a vaccine for the coronavirus, now drugmaker AstraZeneca is the latest to receive funding to generate a panacea.